Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.545 USD | +0.99% | -2.50% | -39.79% |
Apr. 26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
Apr. 25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.79% | 564M | |
+1.03% | 42.86B | |
+13.73% | 42.74B | |
+44.98% | 41.36B | |
-6.20% | 27.68B | |
+6.69% | 25.15B | |
-23.53% | 18.63B | |
+29.55% | 12.37B | |
-2.87% | 11.92B | |
+7.06% | 11.21B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers